Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.

ABSTRACT: Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission. Using country-specific vaccine uptake rates for seasonal influenza, we found that vaccination of older adults would prevent hospitalizations by a median of 35-64% across the countries studied here. Vaccination of pregnant women could avert infant hospitalizations by 5-50%. Reductions in RSV-relate

SUBMITTER: Du Z 

PROVIDER: S-EPMC11835734 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature